Syntara Ltd (SNT)

Currency in AUD
0.057
0.000(0.00%)
Closed·
SNT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SNT is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.0560.058
52 wk Range
0.0270.095
Key Statistics
Bid/Ask
0.056 / 0.057
Prev. Close
0.057
Open
0.057
Day's Range
0.056-0.058
52 wk Range
0.027-0.095
Volume
1.03M
Average Volume (3m)
9.65M
1-Year Change
103.57%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SNT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.235
Upside
+312.28%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Syntara Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Syntara Ltd Company Profile

Syntara Limited operates as a clinical-stage drug development company that focuses on blood-related cancers in Australia. The company’s lead product candidate is SNT-5505, which is in Phase 2 trial to treat myelofibrosis, myelodysplastic syndrome, hepatocellular carcinoma, and pancreatic cancer, as well as scar prevention. It also develops SNT-4728 in Phase 2 trial for the treatment of neurodegenerative diseases comprising isolated rapid eye movement sleep behavior disorder (IRBD) and Parkinson’s disease; SNT-5382, which is a selective lysyl oxidase-like 2 inhibitor in Phase 1 trial to treat chronic fibrosis; and SNT-8370 for the treatment of inflammation. The company was formerly known as Pharmaxis Ltd and changed its name to Syntara Limited in December 2023. Syntara Limited was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.

Syntara Ltd Earnings Call Summary for Q3/2025

  • Syntara reported $18M cash balance, providing 18-month runway; stock up 3.57% to $3.42 amid investor optimism
  • Lead drug 5505 targets myelofibrosis market valued at $1.9B; company exploring partnerships for clinical studies
  • Key data presentation expected at European Hematology Association meeting in June; FDA guidance anticipated by Q3
  • Revenue growth of 9.03% in last 12 months; stock near 52-week high of $3.97 with 144.29% return over past year
  • Potential risks include delays in MDS trial initiation, critical FDA outcomes, and competitive pressure from JAK inhibitors
Last Updated: 01/05/2025, 03:14
Read Full Transcript

Compare SNT to Peers and Sector

Metrics to compare
SNT
Peers
Sector
Relationship
P/E Ratio
−8.4x−6.8x−0.5x
PEG Ratio
−0.19−0.020.00
Price/Book
5.0x5.5x2.6x
Price / LTM Sales
11.4x15.0x3.3x
Upside (Analyst Target)
312.3%214.3%43.4%
Fair Value Upside
Unlock0.8%7.1%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 0.235
(+312.28% Upside)

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SNT Income Statement

FAQ

What Stock Exchange Does Syntara Trade On?

Syntara is listed and trades on the Sydney Stock Exchange stock exchange.

What Is the Stock Symbol for Syntara?

The stock symbol for Syntara is "SNT."

What Is the Syntara Market Cap?

As of today, Syntara market cap is 92.77M.

What Is Syntara's Earnings Per Share (TTM)?

The Syntara EPS (TTM) is -0.01.

When Is the Next Syntara Earnings Date?

Syntara will release its next earnings report on 27 Oct 2025.

From a Technical Analysis Perspective, Is SNT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Syntara Stock Split?

Syntara has split 1 times.

How Many Employees Does Syntara Have?

Syntara has 21 employees.

What is the current trading status of Syntara (SNT)?

As of 10 Aug 2025, Syntara (SNT) is trading at a price of 0.06, with a previous close of 0.06. The stock has fluctuated within a day range of 0.06 to 0.06, while its 52-week range spans from 0.03 to 0.10.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.